Hsbc Holdings PLC Has $5.56 Million Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Hsbc Holdings PLC cut its position in Exact Sciences Co. (NASDAQ:EXASFree Report) by 2.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 75,004 shares of the medical research company’s stock after selling 1,501 shares during the period. Hsbc Holdings PLC’s holdings in Exact Sciences were worth $5,557,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Johnson Financial Group Inc. raised its holdings in Exact Sciences by 1,637.4% in the fourth quarter. Johnson Financial Group Inc. now owns 5,299 shares of the medical research company’s stock worth $392,000 after purchasing an additional 4,994 shares during the period. Nomura Asset Management Co. Ltd. raised its holdings in shares of Exact Sciences by 8.2% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 46,145 shares of the medical research company’s stock worth $3,414,000 after acquiring an additional 3,500 shares during the period. SageView Advisory Group LLC acquired a new stake in shares of Exact Sciences during the fourth quarter worth $342,000. Annis Gardner Whiting Capital Advisors LLC raised its holdings in shares of Exact Sciences by 19.0% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 6,940 shares of the medical research company’s stock worth $513,000 after acquiring an additional 1,110 shares during the period. Finally, Aigen Investment Management LP raised its holdings in shares of Exact Sciences by 71.2% during the fourth quarter. Aigen Investment Management LP now owns 21,836 shares of the medical research company’s stock worth $1,615,000 after acquiring an additional 9,080 shares during the period. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Sarah Condella sold 2,000 shares of Exact Sciences stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the completion of the sale, the executive vice president now owns 73,787 shares of the company’s stock, valued at approximately $5,165,090. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of Exact Sciences stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total value of $69,473.25. Following the completion of the sale, the chief executive officer now owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sarah Condella sold 2,000 shares of Exact Sciences stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the completion of the sale, the executive vice president now owns 73,787 shares of the company’s stock, valued at approximately $5,165,090. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,498 shares of company stock valued at $370,105. Company insiders own 1.36% of the company’s stock.

Exact Sciences Stock Performance

Shares of EXAS opened at $43.45 on Wednesday. The firm has a 50-day moving average of $59.80 and a 200-day moving average of $63.02. Exact Sciences Co. has a one year low of $43.30 and a one year high of $100.77. The company has a market cap of $8.02 billion, a PE ratio of -32.92 and a beta of 1.26. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.64 and a quick ratio of 1.45.

Exact Sciences (NASDAQ:EXASGet Free Report) last announced its earnings results on Wednesday, May 8th. The medical research company reported ($0.50) EPS for the quarter, hitting the consensus estimate of ($0.50). The business had revenue of $637.52 million during the quarter, compared to the consensus estimate of $624.95 million. Exact Sciences had a negative net margin of 9.48% and a negative return on equity of 7.12%. As a group, equities analysts forecast that Exact Sciences Co. will post -1.15 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on EXAS shares. Canaccord Genuity Group dropped their price objective on shares of Exact Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Citigroup dropped their price objective on shares of Exact Sciences from $100.00 to $80.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. TheStreet downgraded shares of Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. BTIG Research decreased their target price on shares of Exact Sciences from $85.00 to $80.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Finally, Jefferies Financial Group initiated coverage on shares of Exact Sciences in a research report on Monday. They issued a “buy” rating and a $75.00 target price for the company. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.07.

Get Our Latest Research Report on EXAS

Exact Sciences Profile

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

See Also

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.